FDA advisers back Rockwell's Triferic to treat iron loss
This article was originally published in Scrip
Executive Summary
The FDA's Oncologic Drugs Advisory Committee (ODAC) on 6 November voted 8-3 to back approval of Rockwell Medical's Triferic (ferric pyrophosphate) as a treatment for iron loss, declaring the company's efficacy and safety results supported the product's benefit over its risk.